Thursday, February 14, 2008

OraPharma, Inc.’s ARESTIN®


Warminster, PA (February 13, 2008) − OraPharma, Inc., a specialty oral health- company dedicated to bringing scientifically and technologically superior products to the dental community, received several industry accolades in 2007 for its ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg, an adjunct treatment to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis.
Specifically, OraPharma recently received the coveted 2007 Townie Choice Award from Dentaltown. This is the fourth consecutive year that ARESTIN® has received the Townie Choice Award from Dentaltown magazine readers.
In addition, the company received an additional 2007 Townie Choice Award from Hygienetown, making ARESTIN® a three-time winner for the publication, courtesy of the hygienists who use the locally administered antibiotic (LAA) as part of their personal standard of care.
ARESTIN® is featured in the December 2007 “Special Edition” Townie Choice Award issues of both Dentaltown and Hygienetown. The Townie Choice Awards were created to provide dental professionals with another source of information when making difficult purchase decisions. This is the only award in dentistry that comes directly from the professionals who treat patients every day.
“This year, more than 2800 dental professionals voted for the products, services, and equipment that they use every day,” remarked Thomas Giacobbi, DDS, FAGD, editorial director, Dentaltown. “Each and every product chosen by our readers plays an important part in their everyday professional success. The Townie Choice Awards are indeed a profile of our community product loyalties.”
For the complete list of winning Townie Choice products, please pick up the December 2007 “Special Edition” Townie Choice Award issues of Hygienetown and Dentaltown, or log onto www.hygienetown.com or www.dentaltown.com.

Moreover, ARESTIN® was named as one of the “Products Dental Hygienists Cannot Live Without” by a leading independent, nonprofit dental education and product testing foundation (full report is available upon request).

Selected by more than 400 dental teams as a product in the dental professional setting that was most essential and valued by dental professionals, ARESTIN® was reported by 78% of hygienists as a product they depend on routinely to make their practice “easier, faster, better, and more enjoyable.” According to the report, ARESTIN® has gained popularity due to “ease of use.”

In addition, the same independent, nonprofit foundation named ARESTIN®
as one of the best products of the year, receiving the top rating of “Valuable”
based on 79% of 30 evaluators stating they would purchase ARESTIN®.
“We are extremely proud and excited that ARESTIN® was selected by dental professionals as an essential part of their standard of care when treating periodontal disease,” remarked OraPharma’s Product Director, ARESTIN® Marketing, John Lenart. “It’s also encouraging to see that our continuing outreach efforts to increase periodontal disease awareness and comprehensive treatment are having a positive effect for clinicians and the patients they treat.”

About OraPharma, Inc.

OraPharma, Inc. is a specialty pharmaceutical company that discovers, develops, and commercializes therapeutics for the treatment of periodontal disease at various phases of progression. ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg (www.arestin.com) is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. OSSIX™ PLUS™ (resorbable collagen membrane) is used in guided bone regeneration (GBR) and guided tissue regeneration (GTR) procedures. For more information about OraPharma and its products, visit www.orapharma.com.

1 comment:

Spearhead said...

I am curious as to why, in a case where many PCHIPS are required, one cannot administer an oral antibiotic to reduce the cost and arrest the infection in its entirety.